Prelude Corporation, a leader in precision diagnostics for early-stage breast cancer, announced the appointment of Dr. Pat Whitworth as its new Chief Medical Officer. Dr. Whitworth’s extensive clinical and research expertise across the multiple stages of the breast cancer patient journey will bring invaluable leadership as PreludeDx expands its diagnostic portfolio.
“I’m thrilled to join the PreludeDx team during this important growth period and contribute to the mission of improving breast cancer outcomes,” said Dr. Whitworth. “The company’s commitment to personalized medicine with innovative tests like DCISionRT and patient-centered care aligns perfectly with my values.”
Dr. Whitworth brings more than 30 years of clinical expertise to this role and recently served as the Breast Surgical Oncologist and Director at Nashville Breast Center; Medical Director of Aptitude Health; and Associate Professor, Department of Surgery, at the University of Tennessee. His expertise in breast cancer has been acknowledged multiple times as a National Top Doctor.
Also Read: Medical Guardian Acquires MobileHelp, Expanding Senior Health Care Solutions
“Dr. Whitworth’s deep knowledge of breast cancer surgery, his passion for research and his dedication to patient advocacy and innovation, make him an ideal fit for PreludeDx,” said Dan Forche, President and CEO of PreludeDx. “We welcome his leadership in advancing our precision medicine tools, especially at this critical inflection point and entry into the invasive breast cancer market with our AidaBreastTM offering.”
Previously, Dr. Whitworth served as Chair of the Board of Directors for the American Society of Breast Surgeons; Vice Chair of the Breast Committee for the American College of Surgeons Oncology Group (ACOSOG); and Chair of the Research Committee for the ASBrS. He earned his medical degree from the University of Tennessee, completed his residency at the University of Louisville, and his fellowship at M.D. Anderson Cancer Center in cell biology and surgical oncology.
SOURCE: PRNewswire